Anuh Pharma (NSE:ANUHPHR) Net Income From Continuing Operations: ₹410 Mil (TTM As of Mar. 2026)


NSE:ANUHPHR Anuh Pharma Ltd NSE:ANUHPHR
73 GF Score
Price ₹78.89
GF Value ₹104.79
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Anuh Pharma Net Income From Continuing Operations?

Anuh Pharma NSE:ANUHPHR +0.14% 73 Net Income From Continuing Operations is ₹410 Mil as of Mar. 2026. GuruFocus rates NSE:ANUHPHR with a GF Score™ of 73/100 and a GF Value™ of ₹104.79 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Anuh Pharma's net income from continuing operations for the three months ended in Mar. 2026 was ₹117 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2026 was ₹410 Mil.

Anuh Pharma Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Anuh Pharma's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anuh Pharma Net Income From Continuing Operations Chart

Anuh Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Net Income From Continuing Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 391.22 474.70 783.10 610.05 542.21

Anuh Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 124.57 83.01 76.13 134.51 116.81
NSE:ANUHPHR
73GF Score
Anuh Pharma Ltd NSE:ANUHPHR
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anuh Pharma Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹410 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of ₹410 Mil mean?
Anuh Pharma (NSE:ANUHPHR) has a Net Income From Continuing Operations of ₹410 Mil as of Mar. 2026. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Anuh Pharma and its competitors.
Is Anuh Pharma's Net Income From Continuing Operations too high?
Anuh Pharma's current Net Income From Continuing Operations is ₹410 Mil. Overall, Anuh Pharma has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Anuh Pharma's Net Income From Continuing Operations compare to ZTS?
Anuh Pharma's Net Income From Continuing Operations of ₹410 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Drug Manufacturers company?
A good Net Income From Continuing Operations depends on the Drug Manufacturers industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Anuh Pharma and its competitors. Anuh Pharma's current Net Income From Continuing Operations is ₹410 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anuh Pharma stock overvalued right now?
Based on GuruFocus' analysis, Anuh Pharma (NSE:ANUHPHR) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹104.79, compared to a current price of ₹78.89 — trading 24.7% below its estimated fair value. The current Net Income From Continuing Operations is ₹410 Mil. Anuh Pharma's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Anuh Pharma (NSE:ANUHPHR), the current Net Income From Continuing Operations is ₹410 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Anuh Pharma (NSE:ANUHPHR) Overvalued in 2026?

Based on GuruFocus' analysis, Anuh Pharma stock appears to be undervalued. The current stock price of ₹78.89 is trading 24.7% below its estimated GF Value™ of ₹104.79. GuruFocus considers Anuh Pharma to be Modestly Undervalued.

Key valuation signals for NSE:ANUHPHR:

  • Net Income From Continuing Operations: ₹410 Mil
  • GF Value™: ₹104.79 vs. price of ₹78.89 (24.7% below fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the NSE:ANUHPHR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Anuh Pharma Business Description

Other Exchanges 506260:India
Address Dr. Annie Besant Road, North Wing, 3-A, Shiv Sagar Estate, Worli, Mumbai, MH, IND, 400 018
Anuh Pharma Ltd is engaged in the business of manufacturing and selling of Bulk drugs and chemicals. Geographically, it derives a majority of revenue from India. Its product categories include macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and others. The company generates revenue from the sale of Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs.
73GF Score

Get the complete analysis for NSE:ANUHPHR

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹78.89
Price
₹104.79
GF Value